AUTHORS
Yoko Tamamushi, MD, Xiang Zhou, MD, BMBS2, Florian Eisele3, Sofie-Katrin Kadel, MD4, Jessica Peter, MD5, Lukas Scheller, MD6, Sven Neubert7, Tjark Alexander Buchwald8, Cornelia Vogt9, Silvia Nerreter10, Emma Besant11, Shilpa Kurian12, Ann-Sophie Hainold13, Seungbin Han14, Christina Mathilde Verbruggen, PhD15, Umair Munawar, PhD16, Christine Riedhammer17, Sabrina Kraus, MD18, Johannes Waldschmidt, MD19, Torsten Steinbrunn, MD, PhD20, Max Johannes Steinhardt, MD21, Michael Hudecek, MD22, Hermann Einsele, MD, PhD23, Leo Rasche Jr, MD24, K. Martin Kortüm, MD25
AFFILIATIONS
1 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
2 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
3 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
4 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
5 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
6 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
7 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
8 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
9 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
10 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
11 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
12 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
13 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
14 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
15 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
16 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
17 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
18 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
19 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
20 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
21 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
22 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
23 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
24 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
25 University Hospital Wuerzburg, Würzburg, Bavaria, Germany
ABSTRACT
Background: The definition of high-risk (HR) multiple myeloma (MM) remains a matter of debate, as conventional HR criteria may not comprehensively predict outcomes in patients receiving T-cell redirecting therapies (TCRTs) including t-cell engager (TCE) and chimeric antigen receptor (CAR)-T-cell therapy. We present real-world data on SKY92 gene expression profiling in patients with RRMM treated with TCRTs.
Methods: We prospectively analyzed 350 samples of 319 patients treated at the University Hospital of Würzburg, Germany, from November 2019 through July 2026. RRMM was defined as per current International Myeloma Working Group (IMWG) criteria. Patient demographics, disease characteristics, treatment history, and survival outcomes were assessed. HR status was classified according to the 2025 Consensus Genomic Staging (CGS) criteria. Progression-free survival (PFS) was compared across relapse treatment regimens initiated after SKY92 testing.
Results: Overall, the SKY92 assessment was possible in 304/350 samples (86.9%). The remaining 46 samples (13.1%) did not meet predefined quality control. To investigate the impact of SKY92 testing in patients treated with TCRT we focused on RRMM patients and analyzed 132 samples with valid SKY92 test results (median age 64 years, median prior lines of therapy (PL) 3 [range 1-14], 57.9% male, median follow-up of 24.4 months [range 0.06 -78.6], FISH available in 94.7% [n = 125], molecular genetic testing available in 27.3% [n = 36]). HR SKY92 status was identified in 67 patients (50.8%), while 65 patients (49.2%) were classified as standard risk (SR). HR SKY92 classification was associated with significantly shorter PFS compared with SR in this cohort (median 4.3 vs 23.4 months, p < 0.0001).
Overall, a cohort of 63 patients received TCRT within one year after SKY92 testing (median age 59 years, median PL 3 [range 1-10], 63.5% male, median follow-up 41.3 months [range 0.13 -78.6], prior TCRT 17.4% [n = 11], extramedullary disease [EMD] 12.6% [n = 8]). Among these, 28 patients (44.4%) received CAR-T-cell therapy (15 Ciltacabtagen autoleucel, 13 Idecabtagen-vicleucel), 20 (31.7%) BCMA-directed bispecific antibodies (bsAbs), and 15 (23.8%) GPRC5D-directed bsAbs. Prior TCRT exposure was 10.7%, 15.0%, and 33.3%, respectively.
Multivariable analysis adjusted for therapy lines, age, ISS, current CGS status, previous TCRT with the same target, any previous TCRT, EMD, and infiltration grade (Hazard Ratio 2.19, 95% CI 1.00–4.96) was performed and HR SKY92 (n = 32) was found to be associated with significantly shorter PFS than SR (n = 31) (median 7.0 vs 31.6 months, p = 0.0041). Notably, previous TCRT with the same target also remained independently associated with shorter PFS.
Based on available CGS status, 61 patients (96.8%) could be assigned to four risk groups: SKY92 HR/CGS HR (ultra-HR, n = 10), SKY92 HR/CGS SR (n = 21), SKY92 SR/CGS HR (n = 5), and SKY92 SR/CGS SR (n = 23). Patients with ultra-HR had significantly the shortest median PFS (3.1 months), followed by those with SKY92 HR only (7.9 months), CGS HR only (27.0 months), and SR (31.5 months) (log-rank p = 0.0150).
Compared with non-TCRT therapies (n = 36), TCRTs (n = 32) significantly prolonged PFS in patients with HR SKY92 (7.0 vs 3.8 months, p = 0.0110). No significant PFS benefit was observed in patients with SR (31.7 vs 19.0 months, p = 0.2084).
Summary/Conclusion: TCRTs significantly improve PFS in patients with SKY92 HR compared with non-TCRT treatment in RRMM; however, TCRTs do not fully overcome the adverse prognostic impact of the SKY92 high-risk signature. Combined SKY92 and CGS classification further refines risk stratification and define an ultra-high-risk subgroup with particularly poor outcomes, although these findings are based on small subgroup sizes. These findings support the continued clinical value of SKY92 for identifying patients with a persistent unmet need who may benefit from intensified or novel therapeutic strategies. Updated results in an extended cohort will be presented at the meeting.
DISCLOSURES
Yoko Tamamushi, MD: No relevant conflicts of interest to declare.